Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.
Authors
- George Follows (ORCID: https://orcid.org/0000-0002-8489-0762)
- Jeff P. Sharman (ORCID: https://orcid.org/0000-0001-5611-6115)
- Ching Ching Leow
- Catherine C. Coombs (ORCID: https://orcid.org/0000-0003-4656-7304)
- Denise Y. Wang
- Alessandro Sanna (ORCID: https://orcid.org/0000-0002-5015-381X)
- Norbert Grząśko (ORCID: https://orcid.org/0000-0001-7727-4307)
- Marisa Hill
- Zoltán Mátrai (ORCID: https://orcid.org/0000-0003-4104-108X)
- Shuhua Yi (ORCID: https://orcid.org/0000-0002-6291-812X)
- Talha Munir (ORCID: https://orcid.org/0000-0002-2901-0769)
- Lívia Mariano (ORCID: https://orcid.org/0000-0002-9127-9128)
- Lindsey E. Roeker (ORCID: https://orcid.org/0000-0002-3806-059X)
- Katherine Bao (ORCID: https://orcid.org/0000-0001-5377-2387)
- Vishalkumar Patel
- Francesc Bosch (ORCID: https://orcid.org/0000-0001-9241-2886)
- Paul M. Barr (ORCID: https://orcid.org/0000-0002-9733-401X)
- John M. Burke (ORCID: https://orcid.org/0000-0002-5144-6710)
- Sebastian Grosicki (ORCID: https://orcid.org/0000-0003-2644-1050)
- Christine I. Chen
- Matthias Ritgen (ORCID: https://orcid.org/0000-0002-0957-3804)
- Vu Minh Hua
- Ananya Guntur
- Paolo Ghia (ORCID: https://orcid.org/0000-0003-3750-7342)
- Ru Feng (ORCID: https://orcid.org/0000-0001-6135-3545)
- Wojciech J. Jurczak (ORCID: https://orcid.org/0000-0003-1879-8084)
- Bin Liu (ORCID: https://orcid.org/0009-0001-0840-7329)
- Lugui Qiu (ORCID: https://orcid.org/0000-0002-9948-1662)
Institutions
- Medical University of Lublin (PL)
- Universitat Autònoma de Barcelona (ES)
- Memorial Sloan Kettering Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- Medical University of Silesia (PL)
- Eli Lilly (United States) (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University of California, Irvine (US)
- St James's University Hospital (GB)
- Princess Margaret Cancer Centre (CA)
- University of Rochester Medical Center (US)
- UNSW Sydney (AU)
- Sarah Cannon (US)
- Nanfang Hospital (CN)
- Universitäts Hautklinik Kiel (DE)
- IRCCS Ospedale San Raffaele (IT)
- Rocky Mountain Cancer Centers (US)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Willamette Valley Cancer Institute and Research Center (US)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- National Center for Epidemiology (HU)
- University of Florence (IT)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1200/jco-25-00166
- Citations
- 23
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 37.38